Breast cancer

Variations of the BRCA1, BRCA2, CDH1, PTEN, STK11, and TP53 genes increase the risk of developing breast cancer. The AR, ATM, BARD1, BRIP1, CHEK2, DIRAS3, ERBB2, NBN, PALB2, RAD50, and RAD51 genes are associated with breast cancer. Breast cancer is a disease in which certain cells in the breast become abnormal and multiply without control or order to form a tumor. The most common form of breast cancer begins in cells lining the ducts that carry milk to the nipple (ductal cancer). Other forms of breast cancer begin in the glands that produce milk (lobular cancer) or in other parts of the breast. The size, stage, rate of growth, and other characteristics of the tumor determine the kinds of treatment. Treatment may include surgery, drugs (hormonal therapy and chemotherapy), radiation and/or immunotherapy. Surgical removal of the tumor provides the single largest benefit, with surgery alone being capable of producing a cure in many cases. To somewhat increase the likelihood of long-term disease-free survival, several chemotherapy regimens are commonly given in addition to surgery. Most forms of chemotherapy kill cells that are dividing rapidly anywhere in the body, and as a result cause temporary hair loss and digestive disturbances. Radiation may be added to kill any cancer cells in the breast that were missed by the surgery, which usually extends survival somewhat, although radiation exposure to the heart may cause heart failure in the future. Some breast cancers are sensitive to hormones such as estrogen and/or progesterone, which makes it possible to treat them by blocking the effects of these hormones. Prognosis and survival rate varies greatly depending on cancer type and staging. With best treatment and dependent on staging, 5-year relative survival varies from 98% to 23, with an overall survival rate of 85%.

 

Website(s):
  • Welcome to the G2SBC Database Website! The Genes-to-Systems Breast Cancer (G2SBC) Database is a bioinformatics resource that collects and integrates data about genes, transcripts and proteins which have been reported in literature to be altered in breast cancer cells.

Filter

Click on a column header name to sort

OMIM ID NAME PROTEINS TYPE ALIASES ABBREVIATIONS PATHWAY(S) RELATED
604370 breast-ovarian cancer familial type 1 (BROVCA1) BRCA1 breast cancer, CANCER BREAST-OVARIAN CANCER 1, FAMILIAL, SUSCEPTIBILITY
BREAST CANCER 1, FAMILIAL, SUSCEPTIBILITY
OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1
BROVCA1 Fanconi anemia (FA) pathway
114480 breast cancer (BC) BRCA1, BRCA2 (FANCD1), RAD54L, BARD1, ATM, XRCC3, RAD51, FANCN (PALB2), TP53, PPM1D, BACH1/BRIP1 (FANCJ), CHEK2 (CHK2) breast cancer, risk of malignant disease BREAST CANCER, FAMILIAL
BREAST CANCER INCLUDED FAMILIAL MALE
BC Fanconi anemia (FA) pathway, DNA damage response (DDR), homologous recombination (HR)
612555 breast-ovarian cancer familial type 2 (BROVCA2) BRCA2 (FANCD1) blood cell cancer, risk of malignant disease, CANCER, breast cancer Fanconi anemia group D1 protein BROVCA2 Fanconi anemia (FA) pathway, homologous recombination (HR)
no OMIM lobular carcinoma in situ (LCIS) MLH1 breast cancer LCIS Fanconi anemia (FA) pathway, mismatch repair (MMR)

Last modification date: Aug. 22, 2011